Clinical trial
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With…
NCT00432614 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00432614 |
|---|---|
| Title | Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder |
| Official title | A Multi-National, Multi-Center, DB, Placebo-Controlled, Parallel Group, Fixed Dose Efficacy & Safety Study of SR58611A 350 mg Twice Daily vs. Placebo in Adults With Major Depressive Disorder on Concomitant Treatment With Escitalopram 10mg/d |
| Acronym | ALBERIO |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | SR58611A, escitalopram, placebo |
| Enrollment | 510 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Feb 8, 2007 |
| Last update posted | Mar 25, 2009 |
| Countries | Belgium, Estonia, Finland, France, Germany, Greece, India, Malaysia, Morocco, South Korea, Taiwan, Tunisia and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: